This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Canasa

Allergan plc

Drug Names(s): Mesalamine; 5-aminosalicylic acid (5-ASA); Salofalk, MAX-002

Description: The active component of Canasa is 5-ASA, a drug that acts to suppress inflammatory bowel disease. The mode of action of 5-ASA is still under investigation with several biochemical mechanisms being proposed. At present, the action of 5-ASA in treating inflammatory bowel disease appears to be associated with the metabolism of arachidonic acid. Studies suggest that interference of 5-ASA with either leukotriene or prostaglandin metabolism may play a major role in suppressing the inflammatory response mechanism.

Deal Structure: In November 2007, Axcan Pharma announced that it entered into an agreement for Axcan to be acquired by TPG Capital and its affiliates in an all-cash transaction with a total value of approximately US$1.3 billion.

Aptalis and Forest
In January 2014, Aptalis announced that it has signed a definitive agreement to be acquired by Forest Laboratories. Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash, pending required reviews by anti-trust authorities in the US and Canada. Forest expects to use a combination of cash on hand and debt to fund the transaction.

In February 2014, Forest Laboratories announced the completion of its acquisition of Aptalis, a privately held specialty pharmaceutical company focused on gastrointestinal disorders and cystic fibrosis. The companies will now begin combined operations, with Aptalis operating as a subsidiary of Forest Laboratories.

Forest and Actavis
In February 2014, Actavis and...See full deal structure in Biomedtracker


Canasa News

Pink Sheet Axcan Pharma Canasa


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug